Life Science Connect

Diversity & inclusion is — and has been — an important issue for the biopharmaceutical industry. As such, we thought it would be worthwhile to gain some perspective.

Considering many Life Science Leader readers daydream of starting and leading their own biopharmaceutical company someday, we thought it would be informative to host an executive virtual roundtable with three biopharmaceutical company CEOs who have done just that.

Fundraising used to always be done in person. But then COVID hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have actually become quite proficient at the process and the platforms. Three biopharma execs share some best practices of the virtual pitch.

According to Outsourced Pharma Chief Editor, Louis Garguilo, “politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while also discussing the current IP debate in pharma and the origins of the coronavirus.

We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they’ve done in the past.